Basking Biosciences
baskingbiosciences.comLocations
Columbus, OH, USA · Durham, NC, USA · North America
industry
Biotechnology
Size
1 - 10 employees
Stage
Series A
founded in
2019
Basking is developing the first-in-class agent (BB-031) targeting von Willebrand factor (VWF) along with a direct acting reversal agent (BB-025) to immediately reverse the pharmacological effect of BB-031 in the event of bleeding. BB-031 is an RNA aptamer optimized for rapid onset of action and short duration of effect. Basking will initiate a Phase 2 trial in acute ischemic stroke in late 2023 and is exploring further application in pulmonary embolism in preclinical studies. The technology is based on two decades of translational research on RNA aptamers as therapeutic agents for cardiovascular diseases.
Something looks off?Open jobs at Basking Biosciences
This company does not have jobs relevant to this job board at this time.
To view all their jobs, visit their website.
